Stocksigma LogoStocksigma Logo

Wanbury Achieves USFDA Milestones and Expands Global Metformin Business

Wanbury received nine "No DMF Deficiency" letters from the USFDA across Jul鈥揂ug'26 for Metformin HCl, alongside approvals for Paroxetine and

Wanbury Achieves USFDA Milestones and Expands Global Metformin Business

Wanbury Ltd 路 Press Release 路 16 Oct 2026, 6:42 pm

Wanbury Achieves USFDA Milestones and Expands Global Metformin Business Wanbury received nine "No DMF Deficiency" letters from the USFDA across Jul鈥揂ug'26 for Metformin HCl, alongside approvals for Paroxetine and Diphenhydramine HCl. Expanding its API pipeline, the company is validating Quetiapine Fumarate, Sitagliptin, and Empagliflozin, with regulatory filings planned next quarter for semi-regulated markets. In commercial expansions, Wanbury commercialised a Metformin DC business in Saudi Arabia with an annual revenue potential of ~Rs 10 crore, while its customer secured a two-year Metformin supply tender in Mexico valued at ~Rs 15 crore per annum.

Original exchange filing (PDF)

More announcements from Wanbury Ltd

All Wanbury Ltd announcements